MX352950B - Metodo para tratar condiciones neurologicas con glicosidos cardiacos. - Google Patents
Metodo para tratar condiciones neurologicas con glicosidos cardiacos.Info
- Publication number
- MX352950B MX352950B MX2014006702A MX2014006702A MX352950B MX 352950 B MX352950 B MX 352950B MX 2014006702 A MX2014006702 A MX 2014006702A MX 2014006702 A MX2014006702 A MX 2014006702A MX 352950 B MX352950 B MX 352950B
- Authority
- MX
- Mexico
- Prior art keywords
- treating neurological
- neurological conditions
- cardiac glycosides
- cardiac glycoside
- disease
- Prior art date
Links
- 229940097217 cardiac glycoside Drugs 0.000 title abstract 4
- 239000002368 cardiac glycoside Substances 0.000 title abstract 4
- 229930002534 steroid glycoside Natural products 0.000 title abstract 4
- 230000000926 neurological effect Effects 0.000 title abstract 2
- 150000008143 steroidal glycosides Chemical class 0.000 title 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
Abstract
Se proporciona un método para tratar una condición neurológica en un sujeto por medio de la administración de un glicósido cardíaco. La enfermedad de Alzheimer, la enfermedad de Huntington o la apoplejía son tratadas al administrar una cantidad terapéuticamente efectiva de un glicósido cardíaco a un sujeto. El glicósido cardíaco puede estar presente en una forma de dosificación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29381210P | 2010-01-11 | 2010-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX352950B true MX352950B (es) | 2017-12-15 |
Family
ID=44258983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007977A MX2012007977A (es) | 2010-01-11 | 2011-01-10 | Metodo para tratar condiciones neurologicas con glicocidos cardiacos. |
| MX2014006702A MX352950B (es) | 2010-01-11 | 2012-07-09 | Metodo para tratar condiciones neurologicas con glicosidos cardiacos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007977A MX2012007977A (es) | 2010-01-11 | 2011-01-10 | Metodo para tratar condiciones neurologicas con glicocidos cardiacos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8481086B2 (es) |
| EP (1) | EP2523563B1 (es) |
| JP (1) | JP5917413B2 (es) |
| KR (2) | KR101774181B1 (es) |
| CN (1) | CN102834010B (es) |
| AU (4) | AU2011203933B2 (es) |
| BR (1) | BR112012017073A2 (es) |
| CA (1) | CA2786123C (es) |
| ES (1) | ES2638070T3 (es) |
| MX (2) | MX2012007977A (es) |
| RU (2) | RU2582223C2 (es) |
| WO (1) | WO2011085307A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| US10383886B2 (en) | 2010-01-11 | 2019-08-20 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with oleandrin |
| US10307450B2 (en) | 2010-01-11 | 2019-06-04 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| BR112012017073A2 (pt) | 2010-01-11 | 2015-09-01 | Phoenix Biotechnology Inc | Método de tratamento de condições neurológicas com glicosídeos cardíacos |
| WO2012050884A2 (en) * | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CN107412775B (zh) * | 2010-11-22 | 2021-01-05 | 菲尼克斯生物技术公司 | 用夹竹桃属物种或黄花夹竹桃属物种的提取物治疗神经病症的方法 |
| CN104721195B (zh) * | 2013-12-20 | 2018-04-27 | 张震东 | 华蟾素在制备治疗糖尿病胰岛素抵抗的药物中的用途 |
| US9962485B2 (en) * | 2013-12-30 | 2018-05-08 | Cerner Innovation, Inc. | Automatically disassociating medical devices from patients |
| US10596186B2 (en) | 2016-09-14 | 2020-03-24 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infections |
| US10729735B1 (en) | 2016-09-14 | 2020-08-04 | Phoenix Biotechnology, Inc. | Method and compostitions for treating coronavirus infection |
| WO2019055119A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION |
| US10702567B2 (en) | 2016-09-14 | 2020-07-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
| WO2018053123A1 (en) * | 2016-09-14 | 2018-03-22 | Phoenix Biotechnology, Inc. | Method and compositions for treating viral infection |
| US10766855B2 (en) * | 2016-10-13 | 2020-09-08 | Vivacell Biotechnology España, S.L. | Hydroxamate triterpenoid derivatives |
| GB201708456D0 (en) * | 2017-05-26 | 2017-07-12 | Medical Res Council | Senolytic compounds |
| MX2020002884A (es) * | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. |
| US11331291B2 (en) | 2017-09-14 | 2022-05-17 | Phoenix Biotechnology, Inc. | Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders |
| JP2021502977A (ja) | 2017-11-15 | 2021-02-04 | ユニバルシテ ラバル | 神経学的状態、がん、細菌性感染症又はウイルス性感染症の治療及び／又は予防のためのｓｒｓｆ３作用剤の使用 |
| MX2021014579A (es) * | 2019-05-29 | 2022-01-11 | Phoenix Biotechnology Inc | Metodo y composiciones para tratar una infeccion por el virus linfotropico humano de celulas t tipo 1. |
| CN111603473B (zh) * | 2019-09-30 | 2022-11-25 | 上海和黄药业有限公司 | 一种对神经细胞损伤具有保护作用的组合物及其制剂和用途 |
| EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
| RU2020130238A (ru) | 2020-03-31 | 2022-03-14 | Феникс Байотекнолоджи, Инк. | Способ и композиции для лечения коронавирусной инфекции |
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| JP7648195B2 (ja) * | 2020-05-24 | 2025-03-18 | フェニックス・バイオテクノロジー・インコーポレイテッド | オレアンドリンを含む抽出物及びそれを生成する方法 |
| US12097234B2 (en) | 2020-05-24 | 2024-09-24 | Phoenix Biotechnology, Inc. | Extract containing oleandrin and method of production thereof |
| EP4305046A4 (en) * | 2021-03-10 | 2025-01-29 | Gerold Schmitt-Ulms | COMPOUNDS FOR ALTERING LEVELS OF ONE OR MORE ALPHA NKA SUBUNITS AND THEIR USE IN THE TREATMENT OF PRION DISEASES OR BRAIN DISEASES ASSOCIATED WITH A CELLULAR PRION PROTEIN |
| CN114404425A (zh) * | 2022-01-27 | 2022-04-29 | 南京中医药大学 | 一种磷酸二酯酶的抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| EP1513403B1 (en) * | 2002-05-28 | 2017-02-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| MXPA04011276A (es) | 2002-05-28 | 2005-02-14 | Ortho Tain Inc | Dispositivo dentales y sistemas y metodos para distribuir dispositivos dentales. |
| WO2006044916A2 (en) * | 2004-10-18 | 2006-04-27 | Bionaut Pharmaceuticals, Inc. | Use of na+/ k+-atpase inhibitors and antagonists thereof |
| US7402325B2 (en) * | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007016656A2 (en) | 2005-08-02 | 2007-02-08 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders |
| JP4428481B2 (ja) * | 2006-01-16 | 2010-03-10 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| BRPI0820564A2 (pt) * | 2007-11-13 | 2017-05-23 | Phoenix Biotechnology Inc | método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco |
| ES2326065B1 (es) | 2008-03-28 | 2010-07-08 | Consejo Superior De Investigaciones Cientificas (Csic) | Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple. |
| BRPI0912026A2 (pt) * | 2008-04-29 | 2015-10-06 | Oswal Gunvant Devichand | formulação homeopática |
| US9011937B2 (en) | 2010-11-22 | 2015-04-21 | Phoenix Biotechnology, Inc. | Method of treating neurological conditions with extract of Nerium species or Thevetia species |
| BR112012017073A2 (pt) | 2010-01-11 | 2015-09-01 | Phoenix Biotechnology Inc | Método de tratamento de condições neurológicas com glicosídeos cardíacos |
| TWI495307B (zh) | 2013-03-14 | 2015-08-01 | Realtek Semiconductor Corp | 訊號準位決定裝置及方法 |
-
2011
- 2011-01-10 BR BRBR112012017073-2A patent/BR112012017073A2/pt not_active Application Discontinuation
- 2011-01-10 ES ES11732277.6T patent/ES2638070T3/es active Active
- 2011-01-10 KR KR1020167002807A patent/KR101774181B1/ko not_active Expired - Fee Related
- 2011-01-10 EP EP11732277.6A patent/EP2523563B1/en active Active
- 2011-01-10 JP JP2012548205A patent/JP5917413B2/ja not_active Expired - Fee Related
- 2011-01-10 KR KR1020127018043A patent/KR101811462B1/ko not_active Expired - Fee Related
- 2011-01-10 RU RU2012134341/15A patent/RU2582223C2/ru active
- 2011-01-10 MX MX2012007977A patent/MX2012007977A/es active IP Right Grant
- 2011-01-10 AU AU2011203933A patent/AU2011203933B2/en not_active Ceased
- 2011-01-10 CA CA2786123A patent/CA2786123C/en active Active
- 2011-01-10 US US12/987,693 patent/US8481086B2/en not_active Expired - Fee Related
- 2011-01-10 RU RU2016109107A patent/RU2674679C2/ru active
- 2011-01-10 CN CN201180005716.5A patent/CN102834010B/zh not_active Expired - Fee Related
- 2011-01-10 WO PCT/US2011/020672 patent/WO2011085307A1/en not_active Ceased
-
2012
- 2012-07-09 MX MX2014006702A patent/MX352950B/es unknown
-
2013
- 2013-06-04 US US13/909,562 patent/US9220778B2/en active Active
- 2013-06-04 US US13/909,613 patent/US9358293B2/en not_active Expired - Fee Related
-
2016
- 2016-01-12 AU AU2016200181A patent/AU2016200181B2/en not_active Ceased
- 2016-04-15 AU AU2016202421A patent/AU2016202421B2/en not_active Ceased
- 2016-05-02 US US15/143,973 patent/US9877979B2/en not_active Expired - Fee Related
- 2016-11-25 AU AU2016262784A patent/AU2016262784B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016202421B2 (en) | Method of treating neurological conditions with cardiac glycosides | |
| MX345675B (es) | Metodo para tratar condiciones neurologicas con extracto de especie nerium o especie thevetia. | |
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| UA99953C2 (uk) | Лікування релаксином задишки, асоційованої з гострою серцевою недостатністю | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| NZ715595A (en) | Treatment of disease with poly-n-acetyglucosamine nanofibers | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX348412B (es) | Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2. | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| WO2013169291A3 (en) | Method for inducing udp-glucuronosyltransferase activity using pterostilbene | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| TW201129361A (en) | Methods for treating pain | |
| NZ629964A (en) | Method for treating inflammation | |
| IN2014MN01806A (es) | ||
| EA201170970A1 (ru) | Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| EA032959B9 (ru) | Применение бремеланотида в терапии женской сексуальной дисфункции |